Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (MURGY)
割安ファンダメンタル
77
株価
$498.80
時価総額
$64.49B
パート1 · 企業の価値
概要
Munich Re takes on risk that other insurers do not want to carry alone. As a reinsurer, it agrees to cover a share of the claims a primary insurer might face from earthquakes, hurricanes, life and health claims and other large exposures, in exchange for a share of the premium. Through its ERGO subsidiary, it also sells insurance policies directly to households and businesses, mainly in Europe and Asia.
収益の仕組み
Revenue is the premium collected for agreeing to take on risk, whether from another insurer (reinsurance) or directly from a policyholder (ERGO). Profit comes from two sources: an underwriting result, when premiums collected exceed claims paid and expenses, and investment income earned on the funds held between collecting a premium and eventually paying claims. Both depend on pricing risk accurately, which is the core skill of the business.
セグメント別売上高
Property-casualty, life and health risk assumed from other insurers worldwide; the larger and more volatile of the two businesses.
Insurance policies sold directly to retail and commercial customers, mainly in Germany and other European and Asian markets.
競争優位性(moat)
規模の経済 · 狭いUnderwriting catastrophe and life risk well requires decades of loss data, capital strong enough to survive a very bad year, and pricing discipline, which keeps the reinsurance market concentrated among a handful of large global players. The advantage is real but not exclusive: Swiss Re, Hannover Re and others compete on the same basis for the same large ceding companies.
需要を左右する要因
景気循環型Reinsurance pricing moves in multi-year hard and soft cycles driven by recent loss experience rather than by GDP: after a run of large catastrophe losses, prices and terms harden industry-wide, and they soften again once capital rebuilds and competition returns.
主なリスク
- Natural catastrophe and climate risk — Insurance risk, mainly property-casualty underwriting risk, makes up around 60% of the group's regulatory capital requirement. Global natural-disaster losses reached about $224 billion in 2025, of which insurers covered roughly $108 billion, and Munich Re carries a direct share of that exposure.
- Market risk on the investment portfolio — Premiums held between collection and claims payment are invested in bonds and other assets, so swings in interest rates and capital markets affect both investment income and the value of reserves held against future claims.
- Credit and counterparty risk — The group is exposed to the risk that ceding companies, retrocessionaires or bond issuers in its investment portfolio fail to meet their obligations, one of the risk categories tracked under its Solvency II capital model.
強気材料
Buyers argue that rising natural-catastrophe losses are pushing the whole reinsurance market toward firmer pricing and stricter terms, that Munich Re's scale and underwriting discipline let it selectively write the most attractively priced business, and that a fifth straight year of exceeding profit guidance shows the model working through the cycle.
弱気材料
Sellers fear that climate change is making catastrophe losses larger and less predictable than historical models assume, that a prolonged period of soft pricing could follow the current hard market as competitors rebuild capital, and that a sharp move in interest rates could hurt the investment portfolio at the same time claims are rising.
Written by the editors, published on 2026年8月18日
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
RGA is the direct rival of Munich Re's life and health reinsurance business, competing for mortality, morbidity and longevity treaties with the same life insurers.
Swiss Re is the other global full-line reinsurer of Munich Re's size, bidding for the same property-casualty and life reinsurance treaties with the same large primary insurers worldwide.
The other large German reinsurer competes with Munich Re on the same European and international treaty renewals, with a leaner cost structure aimed at the same cedants.
The French group is the fourth European composite reinsurer, competing for the same property-casualty and life & health reinsurance programmes in Europe, Asia and the Americas.
Berkshire's reinsurance arm writes the same large catastrophe and retroactive covers, and its balance-sheet capacity makes it the preferred alternative on the biggest single placements.
The Bermuda-based group competes on the same property-catastrophe and casualty treaty renewals in North America and internationally, alongside its own primary specialty book.
貸借対照表と流動性
売上高
$63.95B
直近12か月(2026/6/30まで)
純利益
$6.87B
直近12か月(2026/6/30まで)
フリーキャッシュフロー
$6.89B
自己資本合計
$33.56B
負債合計
$8.22B
流動比率
0.28
利払い倍率
-
負債/EBITDA
-
一株当たり利益(EPS)
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$1579.56
現在株価
$498.80
安全マージン
+68.4%
適正価値レンジ
$1026.72 - $2132.41
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
9.53
ROE
21.3%
P/B レシオ
1.92
P/FCF
9.36
粗利益率
35.4%
ROIC
20.2%
収益性レーダー
価値創造(経済的モート)
ROIC
20.2%
WACC
7.1%
ROIC − WACC
+13.1 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格(15)
- Price CAGR 11.20%
- ROIC 20.2%
- Gross Margin 35.4%
- P/FCF 9.36
- P/B Ratio 1.92
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- DCF valuation (Undervalued)
- ROE 20.6%
- Analyst Consensus 50% Buy
- Earnings Surprise avg 4.9%
- PEG Ratio 0.23
- Earnings Quality (OCF/NI) 1.08
- Net Margin Trend 8.5% vs 7.8%
不合格(3)
- Current Ratio
- Revenue Growth 5Y -0.2%
- Piotroski F-Score 2/9
データなし(9)
- EPS data insufficient
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Share Dilution (missing shares data)
Piotroski F-スコア
重大な財務上の懸念
利益の質
高品質:利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Christoph Jurecka | CEO & Chairman of Management Board | 51 |
| Dr. Thomas Blunck | Member of Management Board | 60 |
| Dr. Markus Riess | Head of Economics, Sustainability & Public Affairs and Member of Management Board | 59 |
| Ms. Mari-Lizette Malherbe | Member of Management Board | - |
| Mr. Nicholas J. Gartside C.F.A. | Chief Investment Officer & Member of Management Board | 50 |
| Dr. Achim Kassow | Chief Transformation Officer & Member of Management Board | 59 |
| Mr. Stefan Heinrich Golling | Member of Management Board & Labour Relations Director | 48 |
| Ms. Clarisse Kopff | Member of Management Board | - |
| Mr. Michael Kerner | Member of Management Board | - |
| Mr. Andrew James Buchanan | CFO & Member of Management Board | 46 |
監査リスク
2
取締役会リスク
4
報酬リスク
2
株主権利リスク
1
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for MURGY, sourced from Markets Gazette.